One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
Effect of Celecoxib vs Placebo as Adjuvant Therapy on Disease-Free Survival Among Patients With Breast Cancer: The REACT Randomized Clinical Trial
R. Charles Coombes, MD, PhD1,2; Holly Tovey, MSc3; Lucy Kilburn, MSc3; Janine Mansi, MD4; Carlo Palmieri, MD, PhD5; John Bartlett, PhD6,7; Jonathan Hicks, MD8; Andreas Makris, MD9; Abigail Evans, MD10; Sibylle Loibl, MD11; Carsten Denkert, MD12; Elisabeth Murray, MB, ChB13; Robert Grieve, MD14; Robert Coleman, MD, PhD15; Annabel Borley, MD16; Marcus Schmidt, MD17; Beate Rautenberg, DrMed18; Catarina Alisa Kunze, MD12; Uwe Rhein, MD19; Keyur Mehta, MBA11; Kelly Mousa, MSc1,2; Tessa Dibble, BSc1,2; Xiao Lou Lu, MSc1,2; Gunter von Minckwitz, MD11; Judith M. Bliss, MSc3; for the Randomized European Celecoxib Trial (REACT) Trial Management Group and Investigators
doi : 10.1001/jamaoncol.2021.2193
JAMA Oncol. 2021;7(9):1291-1301
Is there a benefit for patients who receive celecoxib as an addition to conventional therapy for women with ERBB2 (formerly HER2)–negative primary breast cancer?
Association Between Neuronal Autoantibodies and Cognitive Impairment in Patients With Lung Cancer
Frederik Bartels, MD1,2,3; Mona-Marie Wandrey, MD1,3; Annette Aigner, PhD4; Timo Strönisch, MD1,3; Kimberley Farmer, MD1,3; Kristin Rentzsch, MSc5; Antje Tessmer, MD6; Christian Grohé, MD6; Carsten Finke, MD1,3
doi : 10.1001/jamaoncol.2021.2049
JAMA Oncol. 2021;7(9):1302-1310
Are neuronal autoantibodies associated with impaired cognitive function in patients with lung cancer?
Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma: A Randomized Clinical Trial From the Children’s Oncology Group
Sarah E. S. Leary, MD1,2,3; Roger J. Packer, MD4; Yimei Li, PhD5; Catherine A. Billups, MS5; Kyle S. Smith, PhD6; Alok Jaju, MD7; Linda Heier, MD8; Peter Burger, MD9; Karin Walsh, PsyD10; Yuanyuan Han, PhD5; Leanne Embry, PhD11; Jennifer Hadley, MSc6; Rahul Kumar, PhD6; Jeff Michalski, MD12; Eugene Hwang, MD13; Amar Gajjar, MD14; Ian F. Pollack, MD15; Maryam Fouladi, MD16; Paul A. Northcott, PhD6; James M. Olson, MD, PhD1,2,3
doi : 10.1001/jamaoncol.2021.2224
JAMA Oncol. 2021;7(9):1313-1321
Does carboplatin during radiotherapy or isotretinoin during maintenance chemotherapy improve survival in children with high-risk medulloblastoma?
Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer: The NRG-LU001 Phase 2 Randomized Clinical Trial
Heath Skinner, MD, PhD1; Chen Hu, PhD2,3; Theodoros Tsakiridis, MD, PhD4; Rafael Santana-Davila, MD5; Bo Lu, MD6; Jeremy J. Erasmus, MD7; Anthony J. Doemer, MS8; Gregory M. M. Videtic, MD9; James Coster, MD10; Alex Xuezhong Yang, MD11; Richard Y. Lee, MD, PhD12; Maria Werner-Wasik, MD6; Philip E. Schaner, MD, PhD13; Steven E. McCormack, MD14; Benjamin T. Esparaz, MD15; Ronald C. McGarry, MD, PhD16; Jose Bazan, MD17; Timothy Struve, MD18; Rebecca Paulus, BS2; Jeffrey D. Bradley, MD19
doi : 10.1001/jamaoncol.2021.2318
JAMA Oncol. 2021;7(9):1324-1332
Does metformin improve outcomes in nondiabetic, unresectable stage III non–small cell lung cancer (NSCLC) treated with chemoradiation?
Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer: The OCOG-ALMERA Randomized Clinical Trial
Theodoros Tsakiridis, MD, PhD1,2,3; Gregory R. Pond, PhD1,2,4; Jim Wright, MD1,2; Peter M. Ellis, MD1,2; Naseer Ahmed, MD5; Bassam Abdulkarim, MD, PhD6; Wilson Roa, MD7; Andrew Robinson, MD8; Anand Swaminath, MD1,2; Gordon Okawara, MD1,2; Marcin Wierzbicki, PhD1,2; Mario Valdes, MD9; Mark Levine, MD1,2,4
doi : 10.1001/jamaoncol.2021.2328
JAMA Oncol. 2021;7(9):1333-1341
Could the addition of metformin to chemoradiotherapy, as a concurrent treatment as well as consolidation therapy, improve outcomes in patients without diabetes who have locally advanced non–small cell lung cancer?
Association of Combination of Conformation-Specific KIT Inhibitors With Clinical Benefit in Patients With Refractory Gastrointestinal Stromal Tumors: A Phase 1b/2a Nonrandomized Clinical Trial
Andrew J. Wagner, MD, PhD1; Paul L. Severson, PhD2; Anthony F. Shields, MD, PhD3; Amita Patnaik, MD4; Rashmi Chugh, MD5; Gabriel Tinoco, MD6; Guoxian Wu, PhD2; Marika Nespi, MS2; Jack Lin, PhD2; Ying Zhang, PhD2; Todd Ewing, PhD2; Gaston Habets, PhD2; Elizabeth A. Burton, PhD2; Bernice Matusow, BS2; James Tsai, MS2; Garson Tsang, BS2; Rafe Shellooe, BS2; Heidi Carias, BS2; Katrina Chan, BS2; Hamid Rezaei, PhD2; Laura Sanftner, PhD2; Adhirai Marimuthu, PhD2; Wayne Spevak, PhD2; Prabha N. Ibrahim, PhD2; Kerry Inokuchi, BS2; Oscar Alcantar, BS2; Glenn Michelson, MD7; Athanasios C. Tsiatis, MD2; Chao Zhang, PhD2; Gideon Bollag, PhD2; Jonathan C. Trent, MD, PhD8; William D. Tap, MD9
doi : 10.1001/jamaoncol.2021.2086
JAMA Oncol. 2021;7(9):1343-1350
Is cotargeting the active and inactive conformations of KIT associated with clinical benefit in refractory gastrointestinal stromal tumor (GIST)?
Pembrolizumab Plus Concurrent Chemoradiation Therapy in Patients With Unresectable, Locally Advanced, Stage III Non–Small Cell Lung Cancer: The Phase 2 KEYNOTE-799 Nonrandomized Trial
Salma K. Jabbour, MD1; Ki Hyeong Lee, MD, PhD2; Nikolaj Frost, MD3; Valeriy Breder, MD, PhD4; Dariusz M. Kowalski, MD, PhD5; Theodore Pollock, DO6; Evgeny Levchenko, MD, PhD7; Noemi Reguart, MD, PhD8; Alex Martinez-Marti, MD9; Baerin Houghton, MBBS, BSc, MM10; Jean-Baptiste Paoli, MD11; Sufia Safina, MD12; Keunchil Park, MD13; Takefumi Komiya, MD14; Amy Sanford, MD15; Vishal Boolell, BSc, MBBS16; Hong Liu, MD17; Ayman Samkari, MD17; Steven M. Keller, MD17; Martin Reck, MD18
doi : 10.1001/jamaoncol.2021.2301
JAMA Oncol. 2021;7(9):1351-1359
Is administration of pembrolizumab plus concurrent chemoradiation therapy (cCRT) effective and safe in patients with locally advanced, stage III non–small cell lung cancer (NSCLC)?
Neoadjuvant Trastuzumab, Pertuzumab, and Docetaxel vs Trastuzumab Emtansine in Patients With ERBB2-Positive Breast Cancer: A Phase 2 Randomized Clinical Trial
Thomas Hatschek, MD1,2; Theodoros Foukakis, MD1,2; Judith Bjöhle, MD1; Tobias Lekberg, MD1; Hanna Fredholm, MD1,3; Ellinor Elinder, MD4; Ana Bosch, MD5; Gyula Pekar, MD6; Henrik Lindman, MD7; Aglaia Schiza, MD8; Zakaria Einbeigi, MD9; Jamila Adra, MD10; Anne Andersson, MD11; Lena Carlsson, MD12; Ann Charlotte Dreifaldt, MD13; Erika Isaksson-Friman, MD14; Susanne Agartz, MSc2; Edward Azavedo, MD15; Per Grybäck, MD16; Mats Hellström, MSc17; Hemming Johansson, MSc17; Claudia Maes, MSc17; Ioannis Zerdes, MD2; Johan Hartman, MD2; Yvonne Brandberg, PhD2; Jonas Bergh, MD1,2
doi : 10.1001/jamaoncol.2021.1932
JAMA Oncol. 2021;7(9):1360-1367
Is the efficacy of the present standard combination of docetaxel, trastuzumab, and pertuzumab different from that of trastuzumab emtansine as neoadjuvant therapy for ERBB2-positive breast cancer?
Nivolumab Plus Ipilimumab vs Nivolumab for Previously Treated Patients With Stage IV Squamous Cell Lung Cancer: The Lung-MAP S1400I Phase 3 Randomized Clinical Trial
Scott N. Gettinger, MD1; Mary W. Redman, PhD2,3; Lyudmila Bazhenova, MD4; Fred R. Hirsch, MD, PhD5; Philip C. Mack, PhD6; Lawrence H. Schwartz, MD7; Jeffrey D. Bradley, MD8; Thomas E. Stinchcombe, MD9; Natasha B. Leighl, MD10; Suresh S. Ramalingam, MD11; Susan S. Tavernier, PhD12; Hui Yu, MD, PhD5; Joseph M. Unger, PhD2,3; Katherine Minichiello, MS2,3; Louise Highleyman, BS2; Vassiliki A. Papadimitrakopoulou, MD13; Karen Kelly, MD6; David R. Gandara, MD6; Roy S. Herbst, MD, PhD1
doi : 10.1001/jamaoncol.2021.2209
JAMA Oncol. 2021;7(9):1368-1377
Does the addition of ipilimumab to nivolumab improve survival in patients with advanced chemotherapy-pretreated immunotherapy-naive squamous cell lung cancer?
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
Kerstin N. Vokinger, MD, JD, PhD, LLM1,2; Thomas J. Hwang, AB1,2; Paola Daniore, MSc1; ChangWon C. Lee, AB2; Ariadna Tibau, MD3,4,5; Thomas Grischott, MD, MSc6,7; Thomas J. Rosemann, MD, PhD6,7; Aaron S. Kesselheim, MD, JD, MPH2
doi : 10.1001/jamaoncol.2021.2026
JAMA Oncol. 2021;7(9):e212026
Was there an association between clinical benefit, launch prices and postlaunch price changes for cancer drugs in the US compared with Europe (England, Germany, and Switzerland)?
Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer
Josee-Lyne Ethier, MD, MSc1,2; Danielle Desautels, MD, MSc3; Andrew Robinson, MD1,2; Eitan Amir, MD, PhD4; Weidong Kong, PhD2; Christopher M. Booth, MD1,2
doi : 10.1001/jamaoncol.2021.2140
JAMA Oncol. 2021;7(9):e212140
What are the real-world survival outcomes associated with use of pertuzumab and trastuzumab emtansine (T-DM1) for ERBB2-positive metastatic breast cancer?
Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA
Michael T. Schweizer, MD1,2; Smruthy Sivakumar, PhD3; Hanna Tukachinsky, PhD3; Ilsa Coleman, BA4; Navonil De Sarkar, PhD4; Evan Y. Yu, MD1,2; Eric Q. Konnick, MD5; Peter S. Nelson, MD1,4; Colin C. Pritchard, MD, PhD5,6; Bruce Montgomery, MD1,7
doi : 10.1001/jamaoncol.2021.2350
JAMA Oncol. 2021;7(9):1378-1382
Can the mutational status of DNA repair genes in advanced prostate cancer be accurately assessed by sequencing primary prostate specimens?
Baseline Evaluation of Cancer Mortality in US States that Expanded Medicaid vs Nonexpansion States
Michelle C. Salazar, MD1,2; Michael F. Kaminski1; Maureen E. Canavan, PhD, MPH1,3; Richard C. Maduka, MD1; Andrew X. Li, MD1; Theresa Ermer, MD1,4,5; Daniel J. Boffa, MD1
doi : 10.1001/jamaoncol.2021.2582
JAMA Oncol. 2021;7(9):1394-1395
Incidence of Axillary Adenopathy in Breast Imaging After COVID-19 Vaccination
Kristin A. Robinson, MD1; Santo Maimone, MD1; Denise A. Gococo-Benore, MD2; Zhuo Li, MS3; Pooja P. Advani, MD4; Saranya Chumsri, MD4
doi : 10.1001/jamaoncol.2021.3127
JAMA Oncol. 2021;7(9):1395-1397
Update on the Diagnosis and Treatment of POEMS (Polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal Gammopathy, and Skin Changes) Syndrome: A Review
Jack Khouri, MD1; Megan Nakashima, MD2; Sandy Wong, MD3
doi : 10.1001/jamaoncol.2021.0586
JAMA Oncol. 2021;7(9):1383-1391
POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome is a rare plasma cell disorder characterized by demyelinating peripheral neuropathy and clonal plasma cell proliferation. Clinical manifestations are believed to be associated with a surge of inflammatory and angiogenic mediators, including interleukins and vascular endothelial growth factor (VEGF), elicited by clonal and polyclonal plasma cells. The clinical manifestations of POEMS syndrome can be debilitating; therefore, early diagnosis is essential. This review discusses several aspects of POEMS syndrome and includes the most recently published findings, with a special emphasis on diagnosis and treatment strategies.
Typical Kidney Tumor With Atypical Presentation
Elizabeth A. Hedges, MD1; Chuong D. Hoang, MD1
doi : 10.1001/jamaoncol.2021.1707
JAMA Oncol. 2021;7(9):1392-1393
Master Protocols and Adaptive Trial Designs to Develop Tumor-Agnostic Drugs for Children: Essential Tools in the Era of the Research to Accelerate Cures and Equity Act
Andrea Arfè, PhD1; Lewis B. Silverman, MD2; Florence Bourgeois, MD, MPH3,4
doi : 10.1001/jamaoncol.2021.1508
JAMA Oncol. 2021;7(9):1281-1282
The Oncology Care Model at 5 Years—Value-Based Payment in the Precision Medicine Era
Samyukta Mullangi, MD, MBA1; Stephen M. Schleicher, MD, MBA2; Ravi B. Parikh, MD, MPP3,4
doi : 10.1001/jamaoncol.2021.1512
JAMA Oncol. 2021;7(9):1283-1284
Atezolizumab in Metastatic Triple-Negative Breast Cancer—No Contradiction in the Eyes of a Dispassionate Observer
Simon Van Wambeke, MD1; Bishal Gyawali, MD, PhD2,3
doi : 10.1001/jamaoncol.2021.1966
JAMA Oncol. 2021;7(9):1285-1286
Anti-inflammatory Agents for Breast Cancer: Case Closed or Is the Jury Still Out?
Wendy Y. Chen, MD, MPH1; Jennifer A. Ligibel, MD1
doi : 10.1001/jamaoncol.2021.2056
JAMA Oncol. 2021;7(9):1289-1290
Unravelling the Mechanisms of Cancer-Related Cognitive Dysfunction in Non–Central Nervous System Cancer
Shawn L. Hervey-Jumper, MD1; Michelle Monje, MD, PhD2
doi : 10.1001/jamaoncol.2021.1900
JAMA Oncol. 2021;7(9):1311-1312
High-risk Medulloblastoma—Balancing the High Stakes of Molecular Profiling to Enhance Treatment Responsivity
Allison M. Martin, MD1; Sadhana Jackson, MD2,3
doi : 10.1001/jamaoncol.2021.2084
JAMA Oncol. 2021;7(9):1322-1323
Forging a Path for Metformin Use in Inoperable Locally Advanced Non–Small Cell Lung Cancer
Chukwuka Eze, MD1; Claus Belka, MD, PhD1,2,3; Farkhad Manapov, MD, PhD1,4
doi : 10.1001/jamaoncol.2021.2316
JAMA Oncol. 2021;7(9):1341-1342
The Cancer Consultation: A Patient Artfully Tutors an Oncologist
Barry R. Meisenberg, MD1
doi : 10.1001/jamaoncol.2021.2523
JAMA Oncol. 2021;7(9):1287-1288
Confession at Bedside
David Haosen Xiang, BA1
doi : 10.1001/jamaoncol.2021.2034
JAMA Oncol. 2021;7(9):1411
Omission of Radiotherapy in Older Adults With Early-Stage Breast Cancer
Varun Kumar Chowdhry, MD1
doi : 10.1001/jamaoncol.2021.2404
JAMA Oncol. 2021;7(9):1397-1398
Omission of Radiotherapy in Older Adults With Early-Stage Breast Cancer—Reply
Mudit Chowdhary, MD1; Arpit M. Chhabra, MD2; Sachin R. Jhawar, MD3
doi : 10.1001/jamaoncol.2021.2407
JAMA Oncol. 2021;7(9):1398-1399
Acupuncture for Cancer Survivors
Sajeenth Vishnu K, BSc (Hons)1; Riccardo Williams, BSc (Hons)1; Ambrutha Sivakumar, BSc (Hons)1
doi : 10.1001/jamaoncol.2021.2514
JAMA Oncol. 2021;7(9):1399
Acupuncture for Cancer Survivors
Mitsuaki Oura, MD1; Fumiya Omata, MD2; Yoshitaka Nishikawa, MD, PhD3
doi : 10.1001/jamaoncol.2021.2517
JAMA Oncol. 2021;7(9):1399-1400
Acupuncture for Cancer Survivors—Reply
Jun J. Mao, MD, MSCE1; Raymond E. Baser, MS2; Katherine S. Panageas, DrPH2
doi : 10.1001/jamaoncol.2021.2520
JAMA Oncol. 2021;7(9):1400-1401
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants—Caution Needed
Ciara Conduit, MBBS1; Roger L. Milne, PhD2,3,4; Kelly-Anne Phillips, MD1,3,5
doi : 10.1001/jamaoncol.2021.2037
JAMA Oncol. 2021;7(9):1401
Bilateral Salpingo-Oophorectomy to Reduce Breast Cancer Risk in Women With Germline BRCA1 or BRCA2 Pathogenic Variants—Caution Needed—Reply
Yun-Hee Choi, PhD1; Mary Beth Terry, PhD2; Laurent Briollais, PhD3,4
doi : 10.1001/jamaoncol.2021.2040
JAMA Oncol. 2021;7(9):1402
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective
Huub H. van Rossum, PhD, EuSpLM1; Lennart J. van Winden, MSc1; Annemieke C. Heijboer, PhD, EuSpLM2
doi : 10.1001/jamaoncol.2021.2043
JAMA Oncol. 2021;7(9):1402-1403
Reporting the Analytical Method Is Essential to Assessing Studies in Which Biomarkers Are a Major Study Objective—Reply
Mattea Reinisch, MD1; Christian Thode, MD2; Sibylle Loibl, MD, PhD3
doi : 10.1001/jamaoncol.2021.2046
JAMA Oncol. 2021;7(9):1403-1404
Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer
Sezin Yuce Sari, MD1; Alper Kahvecioglu, MD1; Ferah Yildiz, MD1
doi : 10.1001/jamaoncol.2021.2110
JAMA Oncol. 2021;7(9):1404
Sequential Chemoradiotherapy vs Concurrent Chemoradiotherapy or Radiotherapy Alone in Adjuvant Treatment for Patients With Cervical Cancer—Reply
He Huang, MD1; Yan-Ling Feng, MD1; Ji-Hong Liu, MD1
doi : 10.1001/jamaoncol.2021.2113
JAMA Oncol. 2021;7(9):1404-1405
